Boston Scientific raised its full-year 2026 net sales outlook to 7.0% to 8.5% reported growth and 6.5% to 8.0% organic growth. It also lifted adjusted EPS guidance to $3.34 to $3.xx, signaling improved expectations for top-line momentum and profitability. The update is modestly positive for shares, though the article provides no detail on the drivers behind the higher outlook.
Boston Scientific raised its full-year 2026 net sales outlook to 7.0% to 8.5% reported growth and 6.5% to 8.0% organic growth. It also lifted adjusted EPS guidance to $3.34 to $3.xx, signaling improved expectations for top-line momentum and profitability. The update is modestly positive for shares, though the article provides no detail on the drivers behind the higher outlook.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialOverall Sentiment
mildly positive
Sentiment Score
0.25
Ticker Sentiment
